Publisher's "Myelofibrosis-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Myelofibrosis epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.
Our epidemiology services include:
- Incidence and prevalence
- Diagnosis rate, treatment rate and mortality patterns
- Epidemiology-based forecasting and disease trends
- Size of different patient segments in a disease area
- Population based: disease occurrence, co-morbidities and treatment patterns
- Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
- Patient treatment journey
- Treatment algorithm and guidelines
- Assesses the disease risk and burden
- Highlights the unmet needs
- Market driver and barrier
- Growth opportunities and market trend analysis
Methodology
- This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
- To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
- All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
TABLE OF CONTENTS1. Report Introduction
2. Myelofibrosis Epidemiology Overview at a Glance
3. Market Share Distribution of Myelofibrosis
4. Disease Background and Overview: Myelofibrosis
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Myelofibrosis Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Myelofibrosis by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Myelofibrosis
7.3. Sub-Type Specific cases of Myelofibrosis-
7.4. Sex- Specific Cases of Myelofibrosis-
7.5. Diagnosed Cases of Myelofibrosis
7.6. Treated Cases of Myelofibrosis
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Myelofibrosis
8.1.3. Sub-Type Specific cases of Myelofibrosis-
8.1.4. Sex- Specific Cases of Myelofibrosis-
8.1.5. Diagnosed Cases of Myelofibrosis
8.1.6. Treated Cases of Myelofibrosis
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Myelofibrosis
8.2.3. Sub-Type Specific cases of Myelofibrosis-
8.2.4. Sex- Specific Cases of Myelofibrosis-
8.2.5. Diagnosed Cases of Myelofibrosis
8.2.6. Treated Cases of Myelofibrosis
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Myelofibrosis
8.3.3. Sub-Type Specific cases of Myelofibrosis-
8.3.4. Sex- Specific Cases of Myelofibrosis-
8.3.5. Diagnosed Cases of Myelofibrosis
8.3.6. Treated Cases of Myelofibrosis
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Myelofibrosis
8.4.3. Sub-Type Specific cases of Myelofibrosis-
8.4.4. Sex- Specific Cases of Myelofibrosis-
8.4.5. Diagnosed Cases of Myelofibrosis
8.4.6. Treated Cases of Myelofibrosis
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Myelofibrosis
8.5.3. Sub-Type Specific cases of Myelofibrosis-
8.5.4. Sex- Specific Cases of Myelofibrosis-
8.5.5. Diagnosed Cases of Myelofibrosis
8.5.6. Treated Cases of Myelofibrosis
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Myelofibrosis
9.3. Sub-Type Specific cases of Myelofibrosis-
9.4. Sex- Specific Cases of Myelofibrosis-
9.5. Diagnosed Cases of Myelofibrosis
9.6. Treated Cases of Myelofibrosis
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About Publisher
- Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Myelofibrosis in 7MM
Table 2: Total Prevalent/Incident Cases of the Myelofibrosis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Myelofibrosis in United States
Table 4: Sub-Type Specific Cases of the Myelofibrosis in United States-
Table 5: Sex- Specific Cases of the Myelofibrosis in United States-
Table 6: Diagnosed Cases of the Myelofibrosis in United States
Table 7: Treated Cases of the Myelofibrosis in United States
Table 8: Prevalent/Incident Cases of the Myelofibrosis in Germany
Table 9: Sub-Type Specific Cases of the Myelofibrosis in Germany-
Table 10: Sex- Specific Cases of the Myelofibrosis in Germany-
Table 11: Diagnosed Cases of the Myelofibrosis in Germany
Table 12: Treated Cases of the Myelofibrosis in Germany
Table 13: Prevalent/Incident Cases of the Myelofibrosis in France
Table 14: Sub-Type Specific Cases of the Myelofibrosis in France-
Table 15: Sex- Specific Cases of the Myelofibrosis in France-
Table 16: Diagnosed Cases of the Myelofibrosis in France
Table 17: Treated Cases of the Myelofibrosis in France
Table 18: Prevalent/Incident Cases of the Myelofibrosis in Italy
Table 19: Sub-Type Specific Cases of the Myelofibrosis in Italy-
Table 20: Sex- Specific Cases of the Myelofibrosis in Italy-
Table 21: Diagnosed Cases of the Myelofibrosis in Italy
Table 22: Treated Cases of the Myelofibrosis in Italy
Table 23: Prevalent/Incident Cases of the Myelofibrosis in Spain
Table 24: Sub-Type Specific Cases of the Myelofibrosis in Spain-
Table 25: Sex- Specific Cases of the Myelofibrosis in Spain-
Table 26: Diagnosed Cases of the Myelofibrosis in Spain
Table 27: Treated Cases of the Myelofibrosis in Spain
Table 28: Prevalent/Incident Cases of the Myelofibrosis in UK
Table 29: Sub-Type Specific Cases of the Myelofibrosis in UK-
Table 30: Sex- Specific Cases of the Myelofibrosis in UK-
Table 31: Diagnosed Cases of the Myelofibrosis in UK
Table 32: Treated Cases of the Myelofibrosis in UK
Table 33: Prevalent/Incident Cases of the Myelofibrosis in Japan
Table 34: Sub-Type Specific Cases of the Myelofibrosis in Japan-
Table 35: Sex- Specific Cases of the Myelofibrosis in Japan-
Table 36: Diagnosed Cases of the Myelofibrosis in Japan
Table 37: Treated Cases of the Myelofibrosis in Japan
- Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Myelofibrosis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Myelofibrosis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Myelofibrosis in United States
Figure 4: Sub-Type Specific Cases of the Myelofibrosis in United States-
Figure 5: Sex- Specific Cases of the Myelofibrosis in United States-
Figure 6: Diagnosed Cases of the Myelofibrosis in United States
Figure 7: Treated Cases of the Myelofibrosis in United States
Figure 8: Prevalent/Incident Cases of the Myelofibrosis in Germany
Figure 9: Sub-Type Specific Cases of the Myelofibrosis in Germany-
Figure 10: Sex- Specific Cases of the Myelofibrosis in Germany-
Figure 11: Diagnosed Cases of the Myelofibrosis in Germany
Figure 12: Treated Cases of the Myelofibrosis in Germany
Figure 13: Prevalent/Incident Cases of the Myelofibrosis in France
Figure 14: Sub-Type Specific Cases of the Myelofibrosis in France-
Figure 15: Sex- Specific Cases of the Myelofibrosis in France-
Figure 16: Diagnosed Cases of the Myelofibrosis in France
Figure 17: Treated Cases of the Myelofibrosis in United France
Figure 18: Prevalent/Incident Cases of the Myelofibrosis in Italy
Figure 19: Sub-Type Specific Cases of the Myelofibrosis in Italy-
Figure 20: Sex- Specific Cases of the Myelofibrosis in Italy-
Figure 21: Diagnosed Cases of the Myelofibrosis in Italy
Figure 22: Treated Cases of the Myelofibrosis in Italy
Figure 23: Prevalent/Incident Cases of the Myelofibrosis in Spain
Figure 24: Sub-Type Specific Cases of the Myelofibrosis in Spain-
Figure 25: Sex- Specific Cases of the Myelofibrosis in Spain-
Figure 26: Diagnosed Cases of the Myelofibrosis in Spain
Figure 27: Treated Cases of the Myelofibrosis in Spain
Figure 28: Prevalent/Incident Cases of the Myelofibrosis in UK
Figure 29: Sub-Type Specific Cases of the Myelofibrosis in UK-
Figure 30: Sex- Specific Cases of the Myelofibrosis in UK-
Figure 31: Diagnosed Cases of the Myelofibrosis in UK
Figure 32: Treated Cases of the Myelofibrosis in UK
Figure 33: Prevalent/Incident Cases of the Myelofibrosis in Japan
Figure 34: Sub-Type Specific Cases of the Myelofibrosis in Japan-
Figure 35: Sex- Specific Cases of the Myelofibrosis in Japan-
Figure 36: Diagnosed Cases of the Myelofibrosis in Japan
Figure 37: Treated Cases of the Myelofibrosis in Japan
- Indication Specific
1. This report provides in depth analysis for changing competitive dynamics and keeps you ahead of competitors
2. It provides a forward looking perspective on different factors driving or restraining market growth
3. It provides a ten-year forecast assessed on the basis of how the market is expected to grow
4. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of various market segments